Alzheimer's is expected to strike as many as 75 million people worldwide by 2030 without effective treatments, likely costing billions of dollars year in care. A successful treatment would pay some of the richest rewards in medicine.

Biogen is entering a field littered with expensive failures from such players as Pfizer Inc and Eli Lilly and Co.

The 166-patient trial of the Biogen drug, aducanumab, tested four groups who each received a different dose against a fifth group who received a placebo.

The treatment led to reductions in brain amyloid, a type of plaque believed to play a key role in the development of Alzheimer's symptoms, according to interim data presented at a medical meeting in Nice, France, on Friday.

And here is another method...
http://www.sciencealert.com/new-alzheimer-s-treatment-fully-restores-memory-function